Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

University of Manitoba, Winnipeg, MB, Canada.

Published: December 2024

Background: In the last decade, virtual reality has become a popular tool for rehabilitation. It is quite useful in spatial rehabilitation for Alzheimer's disease (AD) as it allows safe navigation in a virtual environment which looks realistic. However, a drawback of virtual reality is cybersickness. The symptoms and severities of cybersickness can vary among users. Possible cybersickness symptoms include headache, nausea, disorientation. Cybersickness can be distracting for participants and can affect their performance on the virtual reality task. Hence, in our rehabilitation game called Barn Ruins Navigation (BRN), we used software design mechanisms that would reduce cybersickness, including (1) keeping the field of view to 60 degrees, (2) lowering speed of rotation and translation, (3) using a joystick which causes less cybersickness, and (4) using a laptop screen instead of a head-mounted display. There have been contradicting results on the effects cybersickness has on people with AD. We wanted to test if cybersickness felt by the BRN game differed between people with AD and cognitively healthy adults.

Method: Cybersickness was measured using the Simulator Sickness Questionnaire (SSQ) after playing BRN. Thirty adults were recruited for the BRN validation study between the ages of 20-88. This includes ten younger adults (five males, 26±3.39 years), ten cognitively healthy older adults (three males, 70.7±5.31 years), and ten people living with mild to moderate AD (seven males, 77.8±5.94 years). All participants played the game once.

Result: Regression analysis on the data showed that males had significantly lower SSQ scores by about 17.47 points compared to females (p = 0.0106), while adjusting for participant groups. The AD group had the highest SSQ scores in comparison to cognitively healthy older adults and younger adults while adjusting for sex. Only the younger adults had a statistically lower SSQ score than the AD group by 18 points (p = 0.023).

Conclusion: We found males were less prone to cybersickness than females, matching the cybersickness literature. Our study found people with AD were more prone to cybersickness, however not to a statistically higher degree than cognitively healthy older adults. We would need a larger sample size to draw solid conclusions.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.083889DOI Listing

Publication Analysis

Top Keywords

cognitively healthy
16
virtual reality
12
cybersickness
12
younger adults
12
healthy older
12
older adults
12
cybersickness symptoms
8
years ten
8
lower ssq
8
ssq scores
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Background: In the brain as in other organs, complement contributes to immune defence and housekeeping to maintain homeostasis. Sources of complement may include local production by brain cells and influx from the periphery, the latter severely restricted by the blood brain barrier (BBB) in healthy brain. Dysregulation of complement leads to excessive inflammation, direct damage to self-cells and propagation of injury.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

GSK, Stevenage, Hertfordshire, United Kingdom.

Background: Progranulin (PGRN), a glycoprotein secreted by microglia and neurons, regulates lysosomal function, neuroinflammation, and has neurotrophic effects. Variants in the granulin gene (GRN) that cause a reduction of PGRN in plasma and cerebrospinal fluid (CSF) are associated with an increased risk of Alzheimer's disease (AD). The sortilin receptor (SORT1) on neurons and microglia regulates PGRN degradation.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Background: In a 16-week, 91-patient placebo-controlled clinical study in DLB ("AscenD-LB";NCT04001517), neflamapimod improved outcomes on the CDR Sum-of-Boxes (p = 0.023 vs. placebo) and Timed Up and Go test (p = 0.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Elixiron Immunotherapeutics, Taipei, Taiwan.

Background: Microglial activation is one of the neuropathological hallmarks of Alzheimer's disease (AD). Evidence suggest that chronic activation of microglia cause neuroinflammation and neuronal injuries, contributing to cognitive impairment. Therefore, modulation of microglial pathway like CSF-1R represents an attractive therapeutic strategy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!